Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M, Furuya M, Motoshima T, Lang M, Funasaki S, Ma W, Sun HW, Hasumi H, Huang Y, Kato I, Kadomatsu T, Satou Y, Morris N, Karim BO, Ileva L, Kalen JD, Wilan Krisna LA, Hasumi Y, Sugiyama A, Kurahashi R, Nishimoto K, Oyama M, Nagashima Y, Kuroda N, Araki K, Eto M, Yao M, Kamba T, Suda T, Oike Y, Schmidt LS, Linehan WM. Baba M, et al. Among authors: kamba t. Mol Cancer Res. 2019 Aug;17(8):1613-1626. doi: 10.1158/1541-7786.MCR-18-1235. Epub 2019 May 1. Mol Cancer Res. 2019. PMID: 31043488 Free PMC article.
Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E, Kamoto T, Kanaji T, Maruyama T, Mikami Y, Toda Y, Matsuoka T, Okuno Y, Tsujimoto G, Narumiya S, Ogawa O. Terada N, et al. Among authors: kamba t. Cancer Res. 2010 Feb 15;70(4):1606-15. doi: 10.1158/0008-5472.CAN-09-2984. Epub 2010 Feb 9. Cancer Res. 2010. PMID: 20145136
Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.
Yamasaki T, Kamba T, Kanno T, Inoue T, Shibasaki N, Arakaki R, Yamada T, Kondo K, Kamoto T, Nishiyama H, Ogawa O, Nakamura E. Yamasaki T, et al. Among authors: kamba t. Cancer Sci. 2012 Nov;103(11):2027-37. doi: 10.1111/j.1349-7006.2012.02412.x. Epub 2012 Oct 10. Cancer Sci. 2012. PMID: 22931246 Free PMC article.
STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.
Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S; Japan Immunotherapy SNPs-Study Group for Kidney Cancer. Eto M, et al. Among authors: kamba t. Eur Urol. 2013 Apr;63(4):745-52. doi: 10.1016/j.eururo.2012.09.052. Epub 2012 Sep 28. Eur Urol. 2013. PMID: 23063454 Clinical Trial.
Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.
Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S. Kawano Y, et al. Among authors: kamba t. Cancer Sci. 2016 Jul;107(7):1013-7. doi: 10.1111/cas.12951. Epub 2016 Jun 14. Cancer Sci. 2016. PMID: 27089226 Free PMC article. Clinical Trial.
CCL2 as a potential therapeutic target for clear cell renal cell carcinoma.
Arakaki R, Yamasaki T, Kanno T, Shibasaki N, Sakamoto H, Utsunomiya N, Sumiyoshi T, Shibuya S, Tsuruyama T, Nakamura E, Ogawa O, Kamba T. Arakaki R, et al. Among authors: kamba t. Cancer Med. 2016 Oct;5(10):2920-2933. doi: 10.1002/cam4.886. Epub 2016 Sep 26. Cancer Med. 2016. PMID: 27666332 Free PMC article.
The significance of TIMD4 expression in clear cell renal cell carcinoma.
Yano H, Motoshima T, Ma C, Pan C, Yamada S, Nakayama T, Kitada S, Fujimoto N, Kamba T, Takeya M, Komohara Y. Yano H, et al. Among authors: kamba t. Med Mol Morphol. 2017 Dec;50(4):220-226. doi: 10.1007/s00795-017-0164-9. Epub 2017 Jun 19. Med Mol Morphol. 2017. PMID: 28631038
185 results